The National Institute for Health and Care Excellence updated tobacco guideline recommends cytisinicline as a treatment option for adults aged 18 to 65 who smoke. The drug works by attaching to some of the same neuronal receptors in the brain that nicotine does, reducing the urge to smoke. As with other licenced medicines for treating tobacco dependence, cysisinicline is more likely to be effective when combined with behavioural support.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
